Trending

rare cancer

Tumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from Bayer

Tumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from Bayer

The UK’s cost-effectiveness agency has said it can’t recommend Bayer’s tumour-agnostic drug Vitrakvi for routine use on the

X

Tumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from Bayer

https://pharmaphorum.com/news/tumour-agnostic-drugs-game-changing-says-nice-as-it-rejects-one-from-bayer/

Daiichi Sankyo’s pexidartinib is first FDA-approved drug for rare tumour

Daiichi Sankyo’s pexidartinib is first FDA-approved drug for rare tumour

Daiichi Sankyo’s pexidartinib has become the first FDA-approved therapy for tenosynovial giant cell tumour (TGCT), a rare form

X

Daiichi Sankyo’s pexidartinib is first FDA-approved drug for rare tumour

https://pharmaphorum.com/news/daiichi-sankyos-pexidartinib-is-first-fda-approved-drug-for-rare-tumour/

Daiichi gets speedy FDA review for rare cancer drug

Daiichi gets speedy FDA review for rare cancer drug

Daiichi Sankyo has been given a priority review from the FDA for pexidartinib, which is vying to become

X

Daiichi gets speedy FDA review for rare cancer drug

https://pharmaphorum.com/news/daiichi-speedy-fda-review-rare-cancer-drug/

NICE recommends Pfizer’s Xalkori in rare lung cancer

NICE recommends Pfizer’s Xalkori in rare lung cancer

NICE has issued a Final Appraisal Determination that recommends the use of Pfizer’s Xalkori (crizotinib) in England under the Cancer Drugs Fund (CDF) for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).

X

NICE recommends Pfizer’s Xalkori in rare lung cancer

https://pharmaphorum.com/news/nice-pfizers-xalkori-rare-lung-cancer/

Immunocore’s rare cancer treatment gains UK Promising Medicine designation

Immunocore’s rare cancer treatment gains UK Promising Medicine designation

Immunocore has gained a Promising Innovative Medicines (PIM) designation in the UK for its candidate immunotherapy for patients with metastatic uveal melanoma, a rare tumour of the eye.

X

Immunocore’s rare cancer treatment gains UK Promising Medicine designation

https://pharmaphorum.com/news/immunocores-rare-cancer-treatment-gains-uk-promising-medicine-designation/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com